NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

4 brokerages have issued 12 month target prices for Aridis Pharmaceuticals' shares. Their forecasts range from $7.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' stock price to reach $17.25 in the next year. This suggests a possible upside of 132.9% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

News stories about ARDS stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Aridis Pharmaceuticals.

Aridis Pharmaceuticals saw a increase in short interest in December. As of December 13th, there was short interest totalling 32,200 shares, an increase of 45.7% from the November 28th total of 22,100 shares. Based on an average daily trading volume, of 6,200 shares, the days-to-cover ratio is presently 5.2 days. Currently, 0.6% of the shares of the stock are short sold. View Aridis Pharmaceuticals' Current Options Chain.

Some companies that are related to Aridis Pharmaceuticals include Kamada (KMDA), Sol Gel Technologies (SLGL), MEI Pharma (MEIP), Osmotica Pharmaceuticals (OSMT), BIOFRONTERA AG/ADR (BFRA), Concert Pharmaceuticals (CNCE), Syndax Pharmaceuticals (SNDX), Hookipa Pharma (HOOK), Seres Therapeutics (MCRB), Theratechnologies (THERF), Affimed (AFMD), Aeglea Bio Therapeutics (AGLE), Cerecor (CERC), Advanz Pharma (CXRXF) and Ocular Therapeutix (OCUL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Genocea Biosciences (GNCA) and Krystal Biotech (KRYS).

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $7.41.

Aridis Pharmaceuticals has a market capitalization of $66.00 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]